Join Transform 2021 this July 12-16. Register for the AI event of the year. HOUSTON–(BUSINESS WIRE)–May 3, 2021– ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound IM156, […]
Home »
ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing
– Phase 1 clinical study recruitment in healthy volunteers is expected to start in Q1 2021 – – Pre-clinical studies have demonstrated a strong anti-fibrotic effect in animal models of fibrosis – – Recently completed Phase 1 trial in oncology patients demonstrated good safety profile – HOUSTON–(BUSINESS WIRE)–February 8, 2021– ImmunoMet Therapeutics, Inc., a clinical […]